GlassScriptPhysician profile
Darren M Vigee
NPI 1639195639
$4,832.98
in general payments reported to CMS, 2019-2025
38 companies · $1,174 in 2025
The $1,174 reported for 2025 was more than what 88% of Foot Surgery providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $362 · 2020: $430 · 2021: $1,033 · 2022: $991 · 2023: $303 · 2024: $541 · 2025: $1,174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,713 · Travel and Lodging: $305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,713.30 |
| Travel and Lodging | $304.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $1,640.07 | 2020-2025 | Puraply, Novachor, Affinity |
| Treace Medical Concepts, INC. | $674.08 | 2022-2025 | |
| Stryker Corporation | $359.70 | 2019-2024 | Ortholoc 2 Lapifuse |
| Smith+Nephew, INC. | $355.59 | 2022-2025 | Collagenase Santyl, Versajet, Grafix |
| Horizon Therapeutics Plc | $274.64 | 2019-2022 | |
| Abbott Laboratories | $224.10 | 2021-2022 | |
| Zimmer Biomet Holdings, INC. | $182.22 | 2020-2021 | |
| Pacira Therapeutics, INC. | $114.34 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $107.59 | 2022-2023 | Nuzyra |
| Boston Scientific Corporation | $101.19 | 2019-2025 | Wavewriter Alpha Prime 16 |
| Kci USA, INC. | $66.55 | 2020-2021 | |
| Vertex Pharmaceuticals Incorporated | $59.47 | 2024-2025 | |
| Radius Health, INC. | $58.91 | 2020-2022 | |
| Osiris Therapeutics INC. | $52.80 | 2019 | |
| Neurocrine Biosciences, INC. | $52.20 | 2020-2021 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Polarityte, INC. | $51.69 | 2019 | |
| Novartis Pharmaceuticals Corporation | $38.38 | 2025 | |
| Acorda Therapeutics, INC | $37.17 | 2019-2022 | |
| Grifols USA, LLC | $35.79 | 2023 | Gamunex-C |
| Grt US Holding, INC. | $35.29 | 2020-2021 | |
| Pacira Pharmaceuticals Incorporated | $28.55 | 2022-2025 | Exparel |
| Merck Sharp & Dohme LLC | $26.34 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.58 | 2019 | |
| Biotissue Holdings INC. | $21.89 | 2021 | |
| Saluda Medical Americas, INC. | $20.14 | 2025 | Evoke |
| Nevro Corp. | $18.43 | 2024 | Senza |
| Ucb, INC. | $17.39 | 2025 | Zilbrysq |
| Baudax Bio INC. | $17.04 | 2022 | |
| Medtronic, INC. | $16.51 | 2021 | |
| Depuy Synthes Sales INC. | $16.49 | 2022 | |
| Ibsa Pharma INC. | $16.28 | 2023 | Tirosint, Licart |
| Alnylam Pharmaceuticals INC. | $15.84 | 2020 | |
| Assertio Therapeutics, INC. | $12.89 | 2019 | |
| Scilex Pharmaceuticals INC. | $12.67 | 2019 | |
| Amgen INC. | $12.54 | 2019 | |
| Collegium Pharmaceutical, INC. | $12.43 | 2019 | |
| Medtronic USA, INC. | $11.16 | 2019 | |
| Ermi LLC | $11.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darren Vigee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.